Treatment of visceral leishmaniasis in HIV-infected patients: A randomized trial comparing meglumine antimoniate with amphotericin B

AIDS

Volumn 13, Issue 9, 1999, Pages 1063-1069

  Laguna, Fernando ^a,m   López Vélez, Rogelio ^b   Pulido, Federico ^c   Salas, Ana ^d   Torre Cisneros, Julián ^e   Torres, Enrique ^f   Medrano, Francisco J ^g   Sanz, Jesús ^h   Picó, Gabriela ⁱ   Gómez Rodrigo, Javier ^j   Pasquau, Juan ^k   Alvar, Jorge ^l  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^e HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^h HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

ⁱ HOSPITAL CAN MISSES   (Spain)

^j HOSPITAL SEVERO OCHOA   (Spain)

^k HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^l INSTITUTO DE SALUD CARLOS III   (Spain)

^m Servicio de Enfermedades Infecciosas   (Spain)

more..

Author keywords

Amphotericin B; HIV; Pentavalent antimonials; Treatment; Visceral leishmaniasis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; MEGLUMINE ANTIMONATE;

ADULT; ARTICLE; BONE MARROW BIOPSY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; PANCREATITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VISCERAL LEISHMANIASIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANIMALS; ANTIPROTOZOAL AGENTS; FEMALE; HUMANS; LEISHMANIA; LEISHMANIASIS, VISCERAL; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME;

EID: 0032788920     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199906180-00009     Document Type: Article

References (20)

1. 1. Gradoni L, Scalone A, Gramiccia M, Troinai M. Epidomiological surveillance of leishmaniasis in HIV-1-infected individuals in Italy. AIDS 1996, 10:785-791.
2. 2. Berman JD. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic development in the last 10 years. Clin Infect Dis 1997, 24:684-693.
3. 3. Montalbán C, Calleja JL, Erice A, et al. Visceral leishmaniasis in patients with human immunodeficiency virus. J Infect 1990, 21:261-270.
4. 4. Medrano FJ, Hernández-Quero J, Jiménez E, et al. Visceral leishmaniasis in HIV-1 infected individuals: a common opportunistic infection in Spain? AIDS 1992, 6:1499-1503.
5. 5. Roshental E, Marty P, Poizot-Martin I, et al. Visceral leishmaniasis and HIV-1 co-infection in southern France. Trans R Soc Trop Med Hyg 1995, 89:159-162.
6. 6. Altés J, Salas A, Riera M, et al. Visceral leishmaniasis: another HIV-associated opportunistic infection? Report of eight cases and review of the literature. AIDS 1991, 5:201-207.
7. 7. Laguna F, Adrados M, Alvar J, et al. Visceral leishmaniasis in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 1997, 16:898-903.
8. 8. López-Vélez R, Pérez-Molina JA, Guerrero A, et al. Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am J Trop Med Hyg 1998, 58:436-443.
9. 9. Alvar J, Cañavate C, Gutiérrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997, 10:298-319.
10. 10. Mishra M, Biswas UK, Jha AM, Khan AB. Amphotericin versus sodium stibogluconate in the first-line treatment of Indian kala-azar. Lancet 1994, 344:1599-1600.
11. 11. Mishra M, Biswas UK, Jha DN, Khan AB. Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet 1992, 340:1256-1257.
12. 12. Murray HW, Hariprashad J, Fichtl RE. Treatment of experimental visceral leishmaniasis in a T-cell-deficient host: response to amphotericin B and pentamidine. Antimicrob Agents Chemother 1993, 37:1504-1505.
13. 13. Faraut-Cambarelli F, Piarroux R, Deniau M, et al. In vitro and in vivo resistance of Leishmania infantum to meglumine antimoniate: a study of 37 strains collected from patients with visceral leishmaniasis. Antimicrob Agents Chemother 1997, 41:827-830.
14. 14. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992, 46:296-306.
15. 15. Gasser RA, Magill AJ, Oster CN, Franke ED, Gröl M, Berman JD. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994, 18:83-90.
16. 16. Franke ED, Llanos-Cuentas A, Echevarría J, et al. Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis. Am J Trop Med Hyg 1994, 51:77-82.
17. 17. Thakur CP, Sinha GP, Pandey AK, Barat D, Singh RK. Daily versus alternate-day regimen of treatment of kala-azar: a randomized comparison. Bull WHO 1994, 72:931-936.
18. 10. Llanos A, Cieza J, Bernardo J, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int 1991, 40:302-308.
19. 19. Davidson RN, Di Martino L, Gradoni L, et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 1994, 87:75-81.
20. 20. Russo R, Nigro LC, Minniti S, et al. Visceral leishmaniasis in HIV-infected patients: treatment with high dose liposomal amphotericin B (AmBisome). J Infect 1996, 32:133-137.